Skip to main content

Table 2 Cox multivariate analysis of recurrence/mortality in patients without adjuvant therapy

From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

  Total ER+ and/or PR+ ER- and PR- ER-/PR-/HER2-
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Recurrence
PostM vs. PreM 0.893 (0.598-1.329) 0.5774 1.167 (0.721-1.887) 0.5268 0.813 (0.419-1.548) 0.5300 0.866 (0.378-1.921) 0.7248
T (>2cm vs. ≤2cm) 0.887 (0.601-1.315) 0.5488 0.895 (0.548-1.460) 0.6573 0.900 (0.469-1.796) 0.7572 0.823 (0.388-1.823) 0.6212
LN (+ vs. -) 2.933 (1.978-4.323) <0.0001* 2.451 (1.488-4.018) 0.0005* 3.879 (1.973-7.414) 0.0002* 3.522 (1.484-7.793) 0.0056*
Grade (II+III vs. I) 2.121 (1.294-3.649) 0.0024* 2.182 (1.274-3.921) 0.0039* 2.056 (0.600-12.900) 0.2844 1.947 (0.560-12.290) 0.3309
ER (+ vs. -) 0.723 (0.444-1.193) 0.2026       
PR (+ vs. -) 0.588 (0.370-0.931) 0.0235*       
HER2 (+ vs. -) 1.313 (0.720-2.282) 0.3617 0.947 (0.227-2.660) 0.9276 1.563 (0.754-3.138) 0.2237   
Bcl-2 (+ vs. -) 2.544 (1.512-4.351) 0.0004* 1.568 (0.759-3.802) 0.2398 3.369 (1.681-6.755) 0.0007* 3.321 (1.556-7.231) 0.0021*
Mortality
PostM vs. PreM 0.914 (0.592-1.407) 0.6829 1.252 (0.721-2.174) 0.4219 0.807 (0.418-1.529) 0.5137 0.877 (0.385-1.928) 0.7455
T (>2cm vs. ≤2cm) 1.008 (0.657-1.563) 0.9705 1.098 (0.628-1.933) 0.7436 0.917 (0.470-1.872) 0.8058 0.862 (0.399-1.965) 0.7139
LN (+ vs. -) 3.186 (2.082-4.853 <0.0001* 2.701 (1.532-4.769) 0.0007* 3.749 (1.907-7.178) 0.0002* 3.425 (1.444-7.576) 0.0065*
Grade (II+III vs. I) 2.431 (1.364-4.672) 0.0020* 2.577 (1.358-5.316) 0.0031* 1.871 (0.547-11.728) 0.3575 1.795 (0.519-11.302) 0.3963
ER (+ vs. -) 0.602 (0.354-1.032) 0.0646       
PR (+ vs. -) 0.534 (0.316-0.894) 0.0169*       
HER2 (+ vs. -) 1.406 (0.762-2.485) 0.2667 1.237 (0.293-3.557) 0.7363 1.653 (0.795-3.337) 0.1742   
Bcl-2 (+ vs. -) 2.399 (1.385-4.205) 0.0017* 1.222 (0.578-3.004) 0.6210 3.143 (1.559-6.306) 0.0016* 3.081 (1.432-6.719) 0.0043*
  1. Factors considered other than Bcl-2 is menopausal status, tumor size, nodal status, grade, ER, PR and HER2 status
  2. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, PostM and PreM postmenopause and premenopause at the time of diagnosis, T tumor size, LN lymph node, + positive; − negative
  3. *Significant, P < 0.05.